Skip to main content
PRLD logo

PRLD · Prelude Therapeutics Inc · Investor Relations

Track PRLD — free
$3.23 -0.03 (-0.77%) At close · Nov 20 Play latest call Q3 2025 earnings call transcript
Market Cap
$258.63M
Shares
80.07M
Volume · Nov 20 300.1K Avg daily vol (3M) 434.45K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date Event Type
2026-12-02 12:55 UTC 9th Annual Evercore Healthcare Conference Conference

Recent news

Date Headline
2026-11-16 Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-10-16 Prelude Therapeutics to Participate in the Chardan Healthcare Conference
2026-10-13 Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
2026-09-10 Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
2026-08-11 Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-05-12 Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-04-21 Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
2026-04-20 Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
2026-03-10 Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
2026-02-03 Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
2025-11-12 Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2025-11-04 Prelude Therapeutics Announces Strategic Business Update
2025-11-04 Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

Past events

Source: https://preludetx.com/investors/

Key facts CIK 1678660 CUSIP 74065P101 13F (30d) 104 filings 90 filers Visit website Investor relations